Clinical Trials List
Protocol NumberETUS20GPC3AR124
Active
2024-03-29 - 2039-03-28
Phase I/II
Recruiting1
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Sponsor
-
Trial scale
Taiwan Single Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 柯博升 主治醫師 Division of Hematology & Oncology
- 陳柏邑 Division of Hematology & Oncology
- 林宗哲 Division of Hematology & Oncology
- Ming-Che Kuo Division of General Internal Medicine
- Ying-Chun Shen Division of Hematology & Oncology
- 劉高郎 Division of Radiology
- 莊建淮 Division of Hematology & Oncology
- 陳睿哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
10-15 participants
-
Global
29-39 participants
